GlassScriptPhysician profile
James Anthony Wrzosek
NPI 1891929618
$11,696.04
in general payments reported to CMS, 2019-2025
20 companies · $6,515 in 2025
The $6,515 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $13.90 · 2021: $310 · 2022: $850 · 2023: $525 · 2024: $3,185 · 2025: $6,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,590 · Consulting Fee: $3,800 · Travel and Lodging: $1,825 · Education: $10.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,589.53 |
| Consulting Fee | $3,800.00 |
| Travel and Lodging | $1,824.72 |
| Education | $10.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $7,443.59 | 2019-2025 | Lensx, Clareon, Clareon Panoptix Pro |
| Biotissue Holdings INC. | $835.10 | 2021-2025 | |
| Rayner Intraocular Lenses Limited | $598.03 | 2022-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Abbvie INC. | $469.69 | 2022-2025 | Durysta, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $358.42 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Ocular Therapeutix, INC. | $348.10 | 2019-2025 | Dextenza |
| Harrow Eye, LLC | $278.64 | 2024-2025 | Vevye, Triesence, Iheezo |
| Tarsus Pharmaceuticals, INC. | $268.11 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $223.42 | 2022-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $169.65 | 2019-2024 | Cequa |
| Ani Pharmaceuticals, INC. | $163.68 | 2024-2025 | Purified Cortrophin Gel |
| Johnson & Johnson Surgical Vision, INC. | $121.95 | 2024 | Tecnis Simplicity |
| Allergan, INC. | $107.10 | 2020-2022 | |
| Dompe US, INC. | $90.78 | 2019-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $58.35 | 2022-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $57.15 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Horizon Therapeutics Plc | $35.03 | 2022-2023 | Tepezza |
| Thea Pharma INC. | $27.32 | 2023 | |
| Kala Pharmaceuticals, INC. | $22.96 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wrzosek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.